Rivaroxaban Viatris (previously Rivaroxaban Mylan)

Negara: Uni Eropa

Bahasa: Yunani

Sumber: EMA (European Medicines Agency)

Bahan aktif:

rivaroxaban

Tersedia dari:

Mylan Ireland Limited

Kode ATC:

B01AF01

INN (Nama Internasional):

rivaroxaban

Kelompok Terapi:

Αντιθρομβωτικοί παράγοντες

Area terapi:

Venous Thromboembolism; Pulmonary Embolism; Acute Coronary Syndrome; Stroke; Coronary Artery Disease; Peripheral Arterial Disease; Atrial Fibrillation

Indikasi Terapi:

Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.  Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.  ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.  Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. -------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Ringkasan produk:

Revision: 4

Status otorisasi:

Εξουσιοδοτημένο

Tanggal Otorisasi:

2021-11-12

Selebaran informasi

The website encountered an unexpected error. Please try again later.

Karakteristik produk

The website encountered an unexpected error. Please try again later.